GGrantIndex
← Leaderboards

Joyce D Fingeroth

Beth Israel Deaconess Medical Center

$3,766,291
Attributed
$3,766,291
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $545.8K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$3,766,291 · 6

By mechanism

R01$2,726,083 · 2
K24$436,301 · 1
R21$333,280 · 1
R03$170,627 · 1
R41$100,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Beth Israel Deaconess Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Gene Expression

Research focus

Gene ExpressionEpstein Barr VirusClinical ResearchImmune SystemMonoclonal AntibodyProteinsSplenic Red PulpComplexInvestigationSpleenCommunicable DiseasesMalignant NeoplasmsCellsPathogenAntigensEvolutionLeadCytoplasmFiltrationBaseAutoimmune DiseasesProtein Structure FunctionHuman TissueGanciclovir

Grant awards (18)

Development of Robust Culture Systems for the Human Splenic Littoral Cell$83,626
R03 · FY2014 · AI · contact PI
Development of Robust Culture Systems for the Human Splenic Littoral Cell$1
R03 · FY2014 · AI · contact PI
Development of Robust Culture Systems for the Human Splenic Littoral Cell$87,000
R03 · FY2013 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling & virus entry$355,790
R01 · FY2009 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling & virus entry$39,440
R01 · FY2009 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling & virus entry$355,790
R01 · FY2008 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling & virus entry$362,680
R01 · FY2007 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling & virus entry$373,512
R01 · FY2006 · AI · contact PI
Formins (FHOS) in CD21-mediated signaling &virus entry$382,500
R01 · FY2005 · AI
The Structural basis of EBV Attachment: CD21 &gp350/220$163,280
R21 · FY2005 · DE
The Structural basis of EBV Attachment: CD21 &gp350/220$170,000
R21 · FY2004 · DE
TREATMENT OF VIRUS ASSOCIATED PROLIFERATIVE DISORDERS$109,283
K24 · FY2003 · CA
TREATMENT OF VIRUS ASSOCIATED PROLIFERATIVE DISORDERS$109,283
K24 · FY2002 · CA
PATHOGENESIS OF ORAL HAIRY LEUKOPLAKIA$434,514
R01 · FY2001 · DE
TREATMENT OF VIRUS ASSOCIATED PROLIFERATIVE DISORDERS$109,282
K24 · FY2001 · CA
Design of EBVTK substrates to eradicate EBV+ tumors$100,000
R41 · FY2001 · CA
PATHOGENESIS OF ORAL HAIRY LEUKOPLAKIA$421,857
R01 · FY2000 · DE
TREATMENT OF VIRUS ASSOCIATED PROLIFERATIVE DISORDERS$108,453
K24 · FY2000 · CA